Pyrimidine Synthesis Inhibitor drugs compared
Compare all 2 Pyrimidine Synthesis Inhibitor drugs side by side, used for conditions such as multiple sclerosis, relapsing-remitting. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores. The highest-rated is aubagio.
Top-rated pyrimidine synthesis inhibitor: 1. Aubagio · 2. Teriflunomide
| Drug | Generic | Form | Status | Used for | Safety ratingFDA recall-based | Pharmacy pays |
|---|---|---|---|---|---|---|
| Aubagio | Teriflunomide | Tablet | Prescription | Multiple Sclerosis, Relapsing-Remitting | 70/100 | $16 |
| Teriflunomide | — | Tablet | Prescription | Multiple Sclerosis, Relapsing-Remitting | 56/100 | $16 |
The safety rating column is unique to pharmaranks — an independent 0–100 score from FDA regulatory recall data. Higher is safer. Not medical advice.
Best pyrimidine synthesis inhibitor by condition
Full ranking · 2 drugs
Frequently asked questions
What is the Pyrimidine Synthesis Inhibitor drug class?
Pyrimidine Synthesis Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 2 Pyrimidine Synthesis Inhibitor products, each independently rated.
Are all Pyrimidine Synthesis Inhibitor drugs the same?
No. Pyrimidine Synthesis Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.
What conditions do Pyrimidine Synthesis Inhibitor drugs treat?
Per NIH RxClass drug-classification data, Pyrimidine Synthesis Inhibitor drugs are used for conditions including multiple sclerosis, relapsing-remitting.
Which Pyrimidine Synthesis Inhibitor drug is best-rated?
By our independent rating, aubagio currently ranks highest among Pyrimidine Synthesis Inhibitor drugs. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
Sources: the Pyrimidine Synthesis Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.